Skip to content
Homepage
Author:
E.F. Hutton & Co.
Posted Date:
June 26, 2026
E.F. Hutton & Co. Advises VCI Global on $6.87 Million Warrant Exercise at Premium to Market
E.F. Hutton & Co.
June 26, 2026
E.F. Hutton & Co. Appoints Healthcare Investment Banking Veteran and Former Public Company CEO Bryan Kobel as Managing Director
E.F. Hutton & Co.
June 15, 2026
E.F. Hutton & Co. Will Serve as Platinum Sponsor at The SPAC Conference 2026
E.F. Hutton & Co.
June 5, 2026
E.F. Hutton & Co. Appoints Accomplished Capital Markets Executive Adam Kerbis as Managing Director, Head of SPAC Investment Banking
E.F. Hutton & Co.
June 2, 2026
E.F. Hutton & Co. Promotes Geoffrey D. Liddy to Chief Operating Officer
E.F. Hutton & Co.
June 1, 2026
E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement
E.F. Hutton & Co.
May 22, 2026
E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering
E.F. Hutton & Co.
May 18, 2026
E.F. Hutton & Co. Serves as Exclusive Placement Agent on iSpecimen Inc. $2.5 Million Private Placement
E.F. Hutton & Co.
May 12, 2026
E.F. Hutton & Co. Serves as Exclusive M&A Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin Miner
E.F. Hutton & Co.
May 7, 2026
E.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals’ $3.5 Million Public Offering
E.F. Hutton & Co.
March 12, 2026
1
2
3
Next
